

MedReleaf completes cannabis supply agreement with the Alberta Gaming, Liquor & Cannabis Commission

MARKHAM, ON, July 5, 2018 – MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the Company") today announced that it has completed a supply agreement with the Alberta Gaming, Liquor & Cannabis Commission ("AGLC") to supply high quality adult recreational-use cannabis products.

Under the terms of the agreement, MedReleaf is committed to supplying the AGLC with cannabis products in a variety of formats including dried flower and capsules. MedReleaf will be represented on Alberta's cannabis store shelves and online through www.albertacannabis.org under both the San Rafael '71 and AltaVie brands.

San Rafael '71 is inspired by and designed to celebrate the spirit of classic cannabis culture, aimed at discerning adults who are knowledgeable about cannabis products and who value quality and an authentic experience. AltaVie is designed for a premium consumer and those new to cannabis who are curious, selective and interested in general wellness and enrichment.

"The milestone passage of Bill C-45 marks an important opportunity for MedReleaf to forge new relationships in the adult recreational cannabis space," said Neil Closner, CEO of MedReleaf. "With our recent acquisition of the Exeter greenhouse facility bringing our fully funded annual production capacity of 140,000 kilograms, we are well prepared to meet the anticipated high demand for recreational cannabis products and we look forward to working with the AGLC in providing our premium products to fulfill the needs of Albertan consumers."

As Canada's leading supplier of premium medical and recreational cannabis, MedReleaf is recognized for its commitment to cultivating consistent, safe, high-quality cannabis. That same exceptional quality is applied to the cultivation and production of all recreational cannabis products. At the voter-driven 2017 Lift Canadian Cannabis Awards, MedReleaf led the industry by winning LP of the year and placing in 10 different categories including first place awards in several product categories: Top Indica Flower, Top CBD Flower, Top High THC Flower, and Top High CBD Oil.

The agreement is conditional on the adoption by the federal and provincial governments of the necessary regulatory framework.

#

About MedReleaf Corp.

Canada's most awarded licensed producer, MedReleaf is an R&D-driven company dedicated to innovation, operational excellence and the production of top-quality cannabis. Sourced from around the world and carefully cultivated in one of two state-of-the-art ICH-GMP and ISO 9001 certified facilities in Ontario Canada, with a third facility currently in development, premium MedReleaf products are delivered to the global medical market. MedReleaf serves the therapeutic needs of patients seeking safe, consistent and effective medical cannabis and provides a compelling product offering for the adult-use recreational consumer.

For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleaf

Contact Information:

Denise Riposati, Corporate Communications, driposati@medreleaf.com, 289-317-1000 ext. 1118
Dennis Fong, Investor Relations, investorrelations@medreleaf.com, 416-283-9930